Table 2.
- Demographics and basic disease characteristics.
| OCR | NAT | S1P | W/o DMT | HC | |
|---|---|---|---|---|---|
| Patients (number [%]) | 88 [40.7] | 42 [19.5] | 27 [12.5] | 59 [27.3] | 61 |
|
Age (y)
(median [range]) |
50 [20 - 68] | 40 [19 - 71] | 48 [18 - 62] | 49 [22 - 65] | 38 [21 - 73] |
| Sex (% female) | 54.0 | 73.8 | 70.4 | 69.5 | 57.4 |
| Disease duration (y) (median [range]) | 11 [2-38] | 15 [0 - 29] | 17 [1 - 41] | 6 [0 - 10] | – |
|
Duration of current treatment (y)
(median [range]) |
3 [1 - 9] | 9 [0 - 21] | 2 [0 - 11] | – | – |
|
Number of previous therapies
(median [range]) |
1 [0 - 4] | 1 [0 - 4] | 1 [0 - 4] | 0 [0 - 3] | – |
DMT, disease modifying therapy; HC, controls without MS; MS, multiple sclerosis; NAT, natalizumab; OCR, ocrelizumab; S1P, Sphingosine-1-Phosphate Modulator; w/o, without; Y, years.